Bank of America Reaffirms Neutral Rating for Cooper Companies (NASDAQ:COO)

Cooper Companies (NASDAQ:COO)‘s stock had its “neutral” rating restated by analysts at Bank of America in a research note issued on Thursday, Benzinga reports. They presently have a $65.00 price objective on the medical device company’s stock, down from their previous price objective of $80.00. Bank of America‘s target price would suggest a potential upside of 2.39% from the stock’s current price.

A number of other research firms have also weighed in on COO. Weiss Ratings reiterated a “sell (d)” rating on shares of Cooper Companies in a research report on Friday, September 4th. Citigroup reissued a “neutral” rating and issued a $80.00 target price (up from $76.00) on shares of Cooper Companies in a report on Thursday, August 13th. Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Sunday, June 21st. The Goldman Sachs Group set a $61.00 target price on shares of Cooper Companies in a report on Wednesday, May 27th. Finally, JPMorgan Chase & Co. decreased their price objective on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a report on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Cooper Companies has a consensus rating of “Hold” and an average price target of $75.27.

Cooper Companies Stock Down 6.2%

Cooper Companies stock opened at $63.48 on Thursday. Cooper Companies has a twelve month low of $58.89 and a twelve month high of $89.83. The stock’s fifty day simple moving average is $72.42 and its 200-day simple moving average is $70.02. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $12.38 billion, a P/E ratio of 53.80, a P/E/G ratio of 1.77 and a beta of 0.82.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period last year, the firm posted $0.49 EPS. The company’s revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts expect that Cooper Companies will post 4.63 earnings per share for the current fiscal year.

Cooper Companies declared that its Board of Directors has authorized a share repurchase plan on Wednesday, September 9th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the medical device company to purchase up to 22.7% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On Cooper Companies

Several large investors have recently made changes to their positions in COO. California State Teachers Retirement System lifted its stake in shares of Cooper Companies by 6,101.7% during the second quarter. California State Teachers Retirement System now owns 19,460,014 shares of the medical device company’s stock worth $1,395,478,000 after purchasing an additional 19,146,230 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Cooper Companies during the 2nd quarter valued at approximately $1,077,762,000. Generation Investment Management LLP bought a new stake in shares of Cooper Companies in the second quarter worth $356,304,000. Wellington Management Group LLP raised its holdings in Cooper Companies by 332.9% in the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after acquiring an additional 4,756,178 shares in the last quarter. Finally, Jupiter Topco LLC acquired a new stake in Cooper Companies in the second quarter valued at $305,074,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reported fiscal third-quarter adjusted EPS of $1.15, ahead of the $1.11–$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded its share-repurchase authorization from $2 billion to $3 billion, potentially allowing the company to buy back as much as 22.7% of outstanding shares. Management also repurchased $339.1 million of stock during the quarter, supporting per-share value if executed effectively. CooperCompanies Completes Strategic Review
• Neutral Sentiment: GAAP EPS was $2.24, helped substantially by a $307.2 million discrete tax benefit related to the favorable completion of a U.K. tax examination. This benefit improves reported results but is not representative of recurring operating performance. CooperCompanies Reports Third-Quarter Results
• Negative Sentiment: CooperCompanies lowered fiscal 2026 adjusted EPS guidance to $4.51–$4.55, below the roughly $4.63 consensus, and set fourth-quarter EPS guidance at $1.05–$1.09 versus expectations near $1.20. Full-year revenue guidance of $4.229–$4.252 billion also implies modest growth.
• Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because potential offers were not sufficiently attractive. Investors appear disappointed that the company did not unlock value through a sale, particularly amid fertility-related litigation costs and competitive pressure in the IUD market. Reasons Cooper Companies Stock Is Under Pressure

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.